Extraocular Muscle Volumetry for Assessment of Thyroid Eye Disease.
Journal
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
ISSN: 1536-5166
Titre abrégé: J Neuroophthalmol
Pays: United States
ID NLM: 9431308
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
pubmed:
12
10
2021
medline:
6
5
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
In this study we evaluate the diagnostic accuracy of extraocular muscle volumetry in detecting thyroid eye disease and to compare the results with simple measurements of maximal medial rectus (MR) diameter. Cross-sectional study that included 47 eyes of 47 patients with thyroid eye disease and 47 healthy controls. Patients underwent slitlamp examination and imaging consisting of computed tomography scans. Image segmentation and volume measurements were performed by 2 independent researchers. Intraobserver and interobserver reliability testing was also conducted. Total extraocular muscle volume was 7.31 ± 1.88 cm3 and medial volume was 2.38 ± 0.73 cm3 in the study group. In this group, the maximum measured diameter of the MR was 6.67 ± 0.35 mm. MR volume was statistically associated with maximum MR diameter (r = 9.78; P < 0.001). Both MR volume and maximum MR diameter measurements showed good predictive efficacy as shown using receiver operator characteristic curve analysis. Complications of thyroid eye disease are often sight threatening, and timely diagnosis is crucial for the management of the entity and its sequelae. The results of this study imply that simple measurements of maximum MR diameter are sensitive enough to establish diagnosis.
Sections du résumé
BACKGROUND
In this study we evaluate the diagnostic accuracy of extraocular muscle volumetry in detecting thyroid eye disease and to compare the results with simple measurements of maximal medial rectus (MR) diameter.
METHODS
Cross-sectional study that included 47 eyes of 47 patients with thyroid eye disease and 47 healthy controls. Patients underwent slitlamp examination and imaging consisting of computed tomography scans. Image segmentation and volume measurements were performed by 2 independent researchers. Intraobserver and interobserver reliability testing was also conducted.
RESULTS
Total extraocular muscle volume was 7.31 ± 1.88 cm3 and medial volume was 2.38 ± 0.73 cm3 in the study group. In this group, the maximum measured diameter of the MR was 6.67 ± 0.35 mm. MR volume was statistically associated with maximum MR diameter (r = 9.78; P < 0.001). Both MR volume and maximum MR diameter measurements showed good predictive efficacy as shown using receiver operator characteristic curve analysis.
CONCLUSIONS
Complications of thyroid eye disease are often sight threatening, and timely diagnosis is crucial for the management of the entity and its sequelae. The results of this study imply that simple measurements of maximum MR diameter are sensitive enough to establish diagnosis.
Identifiants
pubmed: 34629402
doi: 10.1097/WNO.0000000000001339
pii: 00041327-202203000-00060
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e274-e280Informations de copyright
Copyright © 2021 by North American Neuro-Ophthalmology Society.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Lazarus JH. Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab. 2012;26:273–279.
Kan E, Kan EK, Ecemis G, Colak R. Presence of thyroid associated ophthalmopathy in Hashimoto's thyroiditis. Int J Ophthalmol. 2014;7:644–647.
Cozma I. Variation in thyroid status in patients with Graves' orbitopathy. Acta Endocrinol. 2009;5:191–198.
Jacobson DH, Gorman CA. Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment. Endocr Rev. 1984;5:200–220.
Feldon SE, Weiner JM. Clinical significance of extraocular muscle volumes in Graves' ophthalmopathy: a quantitative computed tomography study. Arch Ophthalmol. 1982;100:1266–1269.
Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev. 1989;10:366–391.
Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008;18:983–988.
Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362:726–738.
Carter KD, Frueh BR, Hessburg TP, Musch DC. Long-term efficacy of orbital decompression for compressive optic neuropathy of Graves' eye disease. Ophthalmology. 1991;98:1435–1442.
Siakallis LC, Uddin JM, Miszkiel KA. Imaging investigation of thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34:S41–S51.
Yoshikawa K, Higashide T, Nakase Y, Inoue T, Inoue Y, Shiga H. Role of rectus muscle enlargement in clinical profile of dysthyroid ophthalmopathy. Jpn J Ophthalmol. 1991;35:175–181.
Peyster RG, Ginsberg F, Silber JH, Adler LP. Exophthalmos caused by excessive fat: CT volumetric analysis and differential diagnosis. AJR Am J Roentgenol. 1986;146:459–464.
Regensburg NI, Kok PH, Zonneveld FW, Baldeschi L, Saeed P, Wiersinga WM, Mourits MP. A new and validated CT based method for the calculation of orbital soft tissue volumes. Invest Ophthalmol Vis Sci. 2008;49:1758–1762.
Ozgen A, Alp MN, Ariyürek M, Tütüncü NB, Can I, Günalp I. Quantitative CT of the orbit in Graves' disease. Br J Radiol. 1999;72:757–762.
Souza AD, Ruiz EE, Cruz AA. Extraocular muscle quantification using mathematical morphology: a semi-automatic method for analyzing muscle enlargement in orbital diseases. Comput Med Imaging Graph. 2007;31:39–45.
Gorman CA. The measurement of change in Graves' ophthalmopathy. Thyroid. 1998;8:539–543.
Kang EM, Yoon JS. Clinical and radiological characteristics of Graves' orbitopathy patients showing spontaneous decompression. J Craniomaxillofac. 2015;43:48–52.
Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol. 1995;119:792–795.
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9–14.
Weis E, Heran MK, Jhamb A, Chan AK, Chiu JP, Hurley MC, Rootman J. Clinical and soft-tissue computed tomographic predictors of dysthyroid optic neuropathy: refinement of the constellation of findings at presentation. Arch Ophthalmol. 2011;129:1332–1336.
Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016;375:1552–1565.
Firbank MJ, Coulthard A. Evaluation of a technique for estimation of extraocular muscle volume using 2D MRI. Br J Radiol. 2000;73:1282–1289.
Hallin ES, Feldon SE. Graves' ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography. Br J Ophthalmol. 1988;72:678–682.
Lee JY, Bae K, Park KA, Lyu IJ, Oh SY. Correlation between extraocular muscle size measured by computed tomography and the vertical angle of deviation in thyroid eye disease. PLoS One. 2016;11:e0148167.
Hallin ES, Feldon SE. Graves' ophthalmopathy: I. Simple CT estimates of extraocular muscle volume. Br J Ophthalmol. 1988;72:674–677.
Ohnishi T, Noguchi S, Murakami N, Tajiri J, Harao M, Kawamoto H, Hoshi H, Jinnouchi S, Futami S, Nagamachi S, Watanabe K. Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements. Radiology. 1994;190:857–862.
Das T, Roos JCP, Patterson AJ, Graves MJ, Murthy R. T2-relaxation mapping and fat fraction assessment to objectively quantify clinical activity in thyroid eye disease: an initial feasibility study. Eye (Lond). 2019;33:235–243.
Li Z, Cestari DM, Fortin E. Thyroid eye disease: what is new to know? Curr Opin Ophthalmol. 2018;29:528–534.
Estcourt S, Quinn AG, Vaidya B. Quality of life in thyroid eye disease: impact of quality of care. Eur J Endocrinol. 2011;164:649–655.
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM. The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy. Eur Thyroid J. 2016;5:9–26.
Marcocci C, Marino M. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy. Best Pract Res Clin Endocrinol Metabol. 2012;26:325–337.
Regensburg NI, Wiersinga WM, Berendschot TT, Potgieser P, Mourits MP. Do subtypes of Graves' orbitopathy exist? Ophthalmology. 2011;118:191–196.
Spadea L, Bianco G, Dragani T, Balestrazzi E. Early detection of P-VEP and PERG changes in opthalmic Graves' disease. Graefes Arch Clin Exp Ophthalmol. 1997;235:501–505.
Gürdal C, Saraç Ö, Genç İ, Kırımlıoğlu H, Takmaz T, Can İ. Ocular surface and dry eye in Graves' disease. Curr Eye Res. 2011;36:8–13.
Wiersinga WM, Regensburg NI, Mourits MP. Differential involvement of orbital fat and extraocular muscles in Graves' ophthalmopathy. Eur Thyroid J. 2013;2:14–21.